Log In
Print this Print this

biosimilar trastuzumab, trastuzumab (PF-05280014)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionBiosimilar of Herceptin trastuzumab, a humanized mAb against epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationBreast cancer
Indication DetailsFirst-line treatment of HER2-positive metastatic breast cancer; Neoadjuvant treatment of HER2-positive breast cancer; Treat metastatic breast cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today